Sara Blasco-Turrión

Dr. Sara Blasco-Turrión

Hospital Clínico Universitario de Valladolid, Valladolid, Castille-Leon, Spain
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SBSara Blasco-Turrión
Sara Blasco-Turrión
AFANA MARIA SERRADOR FRUTOS
ANA MARIA SERRADOR FRUTOS
JJJohn Jose
John Jose
GSGunasekaran Sengotuvelu
Gunasekaran Sengotuvelu
ASAshok Seth
Ashok Seth
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos
Background: The vast majority of transcatheter valve-in-valve (ViV) mitral procedures have been reported with the SAPIEN family. We aimed to report the preliminary experience with the Myval balloon-expandable device in this setting. Methods: Multicenter retrospective study of high-risk surgical patients with mitral bioprosthesis degeneration undergoing transcatheter ViV implantation with Myval device. Results: A total of 11 patients from five institutions were gathered between 2019 and 2022 (age 68 ± 7.8, 63% women). The peak and mean transvalvular gradients were 27 ± 5 mmHg and 14.7 ± 2.3 mmHg, respectively, and the predicted neo-left ventricular outflow tract (neo-LVOT) area was 183.4 ± 56 mm2 (range: 171 to 221 mm2). The procedures were performed via transfemoral access in all cases (through echocardiography-guided transeptal puncture (81.8% transesophageal, 11.2% intracardiac)). Technical success was achieved in all cases, with no significant residual mitral stenosis in any of them (peak 7.2 ± 2.7 and mean gradient 3.4 ± 1.7 mmHg) and no complications during the procedure. There were no data of LVOT obstruction, migration, or paravalvular leak in any case. Mean hospital stay was 3 days, with one major vascular complication and no stroke. At 6-month follow-up, there was one case with suboptimal anticoagulation presenting an increase in the transmitral gradients (mean 15 mmHg) that normalized after optimization of the anticoagulation, but no other relevant events. Conclusions: Transseptal ViV mitral implantation with the balloon-expandable Myval device was feasible and safe avoiding redo surgery in high-risk patients with bioprosthesis degeneration.

1 January 2024 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
GMGiorgio Marengo
Giorgio Marengo
CCCarlos Cortés
Carlos Cortés
JSJuan Pablo Sánchez-Luna
Juan Pablo Sánchez-Luna
JGJose Carlos Gonzalez-Gutiérrez
Jose Carlos Gonzalez-Gutiérrez
JHJavier Gómez Herrero
Javier Gómez Herrero
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos

2 April 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
VPVincenzo Pasceri
Vincenzo Pasceri
FPFrancesco Pelliccia
Francesco Pelliccia
RMRoxana Mehran
Roxana Mehran
GDGeorge Dangas
George Dangas
IPitalo porto
italo porto
MZMarco Zimarino
Marco Zimarino
Background: Dialysis is a rare but serious complication after transcatheter aortic valve replacement. We analyzed the large multicenter TRITAVI (transfusion requirements in transcatheter aortic valve implantation) registry in order to develop and validate a clinical score assessing this risk. Methods and Results: A total of 10 071 consecutive patients were enrolled in 19 European centers. Patients were randomly assigned (2:1) to a derivation and validation cohort. Two scores were developed, 1 including only preprocedural variables (TRITAVIpre) and 1 also including procedural variables (TRITAVIpost). In the 6714 patients of the derivation cohort (age 82±6 years, 48% men), preprocedural factors independently associated with dialysis and included in the TRITAVIpre score were male sex, diabetes, prior coronary artery bypass graft, anemia, nonfemoral access, and creatinine clearance <30 mL/min per m 2 . Additional independent predictors among procedural features were volume of contrast, need for transfusion, and major vascular complications. Both scores showed a good discrimination power for identifying risk for dialysis with C‐statistic 0.78 for TRITAVIpre and C‐statistic 0.88 for TRITAVIpost score. Need for dialysis increased from the lowest to the highest of 3 risk score groups (from 0.3% to 3.9% for TRITAVIpre score and from 0.1% to 6.2% for TRITAVIpost score). Analysis of the 3357 patients of the validation cohort (age 82±7 years, 48% men) confirmed the good discrimination power of both scores (C‐statistic 0.80 for TRITAVIpre and 0.81 for TRITAVIpost score). Need for dialysis was associated with a significant increase in 1‐year mortality (from 6.9% to 54.4%; P =0.0001). Conclusions: A simple preprocedural clinical score can help predict the risk of dialysis after transcatheter aortic valve replacement.

25 February 2021 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
FMFrancisco J. Morales-Ponce
Francisco J. Morales-Ponce
PGPablo González-Pérez
Pablo González-Pérez
SBSara Blasco-Turrión
Sara Blasco-Turrión
JSJuan Antonio Sánchez-Brotons
Juan Antonio Sánchez-Brotons
CCCarmen Collado-Moreno
Carmen Collado-Moreno
PCPilar Caro-Mateo
Pilar Caro-Mateo

1 September 2023 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
SBSara Blasco-Turrión
Sara Blasco-Turrión
MMMaría Plaza Martín
María Plaza Martín
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos
Background: New percutaneous techniques for the management of acute pulmonary embolism (PE) are emerging, but there is lack of data regarding the approach of mobile thrombus in the right chambers, with the added risk of potential thrombus dislodgement that may prevent from mechanical circulatory support devices to be implanted in unstable patients. Case summary: We present the case of a 65-year-old male with cardiogenic shock of unknown aetiology, severe biventricular dysfunction, and large mobile thrombus in the right atrium. Mechanical circulatory support devices could not be implanted, and current thromboaspiration systems were either too small or not available at that time. However, the patient’s condition deteriorated rapidly with thrombus in transit, hence, a novel approach was required: using a deflectable 14 Fr sheath, directional thrombectomy was performed, achieving complete extraction of the thrombi and allowing for circulatory support with extracorporeal membrane oxygenation (ECMO) to be implanted with outstanding results and progressive weaning of all intensive care measures. Discussion: Despite the growing interest in the development of percutaneous strategies for acute PE, there is no evidence-based guidelines regarding the treatment of mobile right heart thrombus. Even though some cases of percutaneous right heart thrombectomy have been reported, it is still a challenging scenario, given the potential risk of thrombus dislodgement and atrial perforation. We describe a novel technique of percutaneous directional thrombectomy in a patient with cardiogenic shock of unknown aetiology and large mobile thrombi in the right atrium as a bridge to ECMO proving to be a feasible alternative to treat thrombus in transit.

27 May 2026 in JACC: Advances
Verified
Journal Article
Open access
Francesco PellicciaFrancesco Pelliccia
Francesco Pelliccia
VPVincenzo Pasceri
Vincenzo Pasceri
GDGeorge Dangas
George Dangas
RMRoxana Mehran
Roxana Mehran
IPItalo Porto
Italo Porto
MZMarco Zimarino
Marco Zimarino
Current guidelines recommend single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement (TAVR) in patients without an indication for anticoagulation. This recommendation is mainly based on a better risk profile in terms of bleeding over dual antiplatelet therapy (DAPT), although data on mortality are inconclusive. We analyzed 6-month and 24-month mortality associated with SAPT and DAPT after femoral TAVR from the Transfusion Requirements in Transcatheter Aortic Valve Implantation registry. The Transfusion Requirements in Transcatheter Aortic Valve Implantation is a multicenter registry including 10,071 patients undergoing TAVR. For the purpose of the present study, 4,557 patients with indication to anticoagulation, nonfemoral access, recent percutaneous coronary intervention, and procedural complications were excluded. The remaining 5,514 patients (age 81 ± 7 years, 51% males) were discharged either on SAPT (n = 3,197) or DAPT (n = 2,317). The SAPT group, compared with the DAPT group, experienced lower 6-month all-cause mortality (2.4% vs 5.4%; log-rank P < 0.0001) and major bleeding (0.5% vs 1.3%; log-rank P = 0.001). SAPT was associated with reduced both cardiovascular (1.3%) and noncardiovascular mortality (1.1%), as compared to DAPT (2.2%, P = 0.008 and 3.2%, P = 0.0001, respectively). At 24-month follow-up, overall mortality remained significantly lower with SAPT vs DAPT (11.7% vs 14.2%; log-rank P = 0.007). Cox regression hazard model confirmed the association of DAPT with 6-month (adjusted HR: 1.69; 95% CI: 1.20-2.37; P = 0.002) and 24-month (adjusted HR: 1.21; 95% 1.01-1.46; P = 0.04) all-cause mortality. In a large real-world population of all comers undergoing TAVR, SAPT was associated with a significantly lower 6-month and 24-month all-cause mortality as compared with DAPT. (Transfusion Requirements in Transcatheter Aortic Valve Implantation [TRITAVI] Study; NCT03740425).